Experience

Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000 shares of common stock of Stoke Therapeutics, Inc., which…

Davis Polk advised the representatives of the several underwriters in connection with the $258 million SEC-registered offering of 3,000,000 shares of common stock of Berkeley Lights,…

Davis Polk advised the sole book-running manager in connection with the $80 million initial public offering of 8,000,000 units of Consonance-HFW Acquisition Corp. Each unit consists of…

Davis Polk advised HusCompagniet A/S on the initial public offering of 9,600,000 existing ordinary shares (excluding any overallotment option shares) sold by HusCompagniet’s shareholders,…

Davis Polk advised the representatives of the several underwriters in connection with the $352 million follow-on offering of 11,000,000 shares of common stock of Jamf Holding Corp. sold by…

Davis Polk is advising the financial adviser to Microchip Technology Incorporated in connection with Microchip’s privately negotiated exchanges of $90 million aggregate principal amount of…

Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public offering of 12,650,000 shares of common stock of Olema Oncology at $19…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $307 million public offering of 4,150,000 shares of common stock…

Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…

Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…